Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
DCTH's Cash to Debt is ranked higher than
92% of the 1176 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. DCTH: No Debt )
DCTH' s 10-Year Cash to Debt Range
Min: 1.97   Max: No Debt
Current: No Debt

Equity to Asset 0.76
DCTH's Equity to Asset is ranked higher than
84% of the 978 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DCTH: 0.76 )
DCTH' s 10-Year Equity to Asset Range
Min: 0.61   Max: 0.84
Current: 0.76

0.61
0.84
Interest Coverage No Debt
DCTH's Interest Coverage is ranked higher than
94% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. DCTH: No Debt )
DCTH' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: -16.38
M-Score: -3.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -1492.19
DCTH's Operating margin (%) is ranked lower than
56% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. DCTH: -1492.19 )
DCTH' s 10-Year Operating margin (%) Range
Min: -15569.65   Max: -1805.8
Current: -1492.19

-15569.65
-1805.8
Net-margin (%) -1296.01
DCTH's Net-margin (%) is ranked lower than
56% of the 1120 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. DCTH: -1296.01 )
DCTH' s 10-Year Net-margin (%) Range
Min: -14990.75   Max: -1625.91
Current: -1296.01

-14990.75
-1625.91
ROE (%) -70.81
DCTH's ROE (%) is ranked lower than
53% of the 1163 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. DCTH: -70.81 )
DCTH' s 10-Year ROE (%) Range
Min: -224.96   Max: -29.56
Current: -70.81

-224.96
-29.56
ROA (%) -55.80
DCTH's ROA (%) is ranked lower than
54% of the 1187 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. DCTH: -55.80 )
DCTH' s 10-Year ROA (%) Range
Min: -157.86   Max: -27.27
Current: -55.8

-157.86
-27.27
ROC (Joel Greenblatt) (%) -839.22
DCTH's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 1182 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.91 vs. DCTH: -839.22 )
DCTH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -194983.33   Max: -161.78
Current: -839.22

-194983.33
-161.78
EBITDA Growth (3Y)(%) -50.60
DCTH's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. DCTH: -50.60 )
DCTH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -50.6   Max: 46.6
Current: -50.6

-50.6
46.6
EPS Growth (3Y)(%) -44.80
DCTH's EPS Growth (3Y)(%) is ranked higher than
52% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. DCTH: -44.80 )
DCTH' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.8   Max: 93.9
Current: -44.8

-44.8
93.9
» DCTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DCTH Guru Trades in Q2 2014

Jim Simons 59,298 sh (New)
» More
Q3 2014

DCTH Guru Trades in Q3 2014

Jim Simons 161,798 sh (+172.86%)
» More
Q4 2014

DCTH Guru Trades in Q4 2014

Jim Simons 260,960 sh (+61.29%)
» More
Q1 2015

DCTH Guru Trades in Q1 2015

Jim Simons 345,098 sh (+32.24%)
» More
» Details

Insider Trades

Latest Guru Trades with DCTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.65
DCTH's P/B is ranked higher than
97% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.15 vs. DCTH: 0.65 )
DCTH' s 10-Year P/B Range
Min: 0.57   Max: 6.18
Current: 0.65

0.57
6.18
P/S 7.33
DCTH's P/S is ranked lower than
51% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.31 vs. DCTH: 7.33 )
DCTH' s 10-Year P/S Range
Min: 6.75   Max: 1077.33
Current: 7.33

6.75
1077.33
EV-to-EBIT 0.43
DCTH's EV-to-EBIT is ranked higher than
100% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 42.19 vs. DCTH: 0.43 )
DCTH' s 10-Year EV-to-EBIT Range
Min: -2.5   Max: 0.5
Current: 0.43

-2.5
0.5
Current Ratio 4.73
DCTH's Current Ratio is ranked higher than
86% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. DCTH: 4.73 )
DCTH' s 10-Year Current Ratio Range
Min: 0.58   Max: 67.13
Current: 4.73

0.58
67.13
Quick Ratio 4.66
DCTH's Quick Ratio is ranked higher than
88% of the 1057 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. DCTH: 4.66 )
DCTH' s 10-Year Quick Ratio Range
Min: 0.58   Max: 67.13
Current: 4.66

0.58
67.13
Days Inventory 520.48
DCTH's Days Inventory is ranked higher than
54% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. DCTH: 520.48 )
DCTH' s 10-Year Days Inventory Range
Min: 669.79   Max: 5170.83
Current: 520.48

669.79
5170.83
Days Sales Outstanding 94.66
DCTH's Days Sales Outstanding is ranked higher than
70% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. DCTH: 94.66 )
DCTH' s 10-Year Days Sales Outstanding Range
Min: 59.41   Max: 161.25
Current: 94.66

59.41
161.25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.81
DCTH's Price/Net Cash is ranked higher than
100% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DCTH: 0.81 )
DCTH' s 10-Year Price/Net Cash Range
Min: 0.79   Max: 62.95
Current: 0.81

0.79
62.95
Price/Net Current Asset Value 0.72
DCTH's Price/Net Current Asset Value is ranked higher than
100% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DCTH: 0.72 )
DCTH' s 10-Year Price/Net Current Asset Value Range
Min: 0.72   Max: 44.4
Current: 0.72

0.72
44.4
Price/Tangible Book 0.65
DCTH's Price/Tangible Book is ranked higher than
97% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. DCTH: 0.65 )
DCTH' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 44.06
Current: 0.65

0.9
44.06
Price/Median PS Value 0.17
DCTH's Price/Median PS Value is ranked higher than
99% of the 1294 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.51 vs. DCTH: 0.17 )
DCTH' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 19.7
Current: 0.17

0.18
19.7
Earnings Yield (Greenblatt) 232.60
DCTH's Earnings Yield (Greenblatt) is ranked higher than
99% of the 1174 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DCTH: 232.60 )
DCTH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 185.6   Max: 8625
Current: 232.6

185.6
8625

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DV3.Germany,
Delcath Systems Inc is a Delaware corporation, incorporated on August 5, 1988. The Company is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. It is a specialty pharmaceutical and medical device company developing its proprietary product—Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). In Europe, its proprietary system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). Its primary focus is on the execution of its clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver), and certain other cancers that are metastatic to the liver. The Company currently operates in one business segment, which is the development and commercialization of CHEMOSAT/Melphalan/HDS. Its competitors include Covidian, Biocompatibles, Merit, CeleNova, SirTex, AngioDynamics, and many others. The Company currently holds seven United States patents, ten foreign patents with patent validity in 15 countries, four pending United States patent applications, and two pending foreign patent applications. The Company's products are subject to extensive and rigorous government regulation by foreign regulatory agencies and the FDA.
» More Articles for DCTH

Headlines

Articles On GuruFocus.com
comment on DCTH Mar 15 2013 
Weekly CFO Buys Highlight: BWEN, EMC, INO, DCTH, ACCO Jun 11 2012 
cooldecency99 note on DCTH May 01 2010 
cooldecency99 note on DCTH May 01 2010 
Delcath Systems Inc. Reports Operating Results (10-Q) Oct 23 2009 

More From Other Websites
ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open... May 21 2015
ICC Cohort Of Delcath's Global Phase 2 Trial Of Melphalan/HDS In Hepatocellular Carcinoma Now Open... May 21 2015
DELCATH SYSTEMS, INC. Financials May 20 2015
10-Q for Delcath Systems, Inc. May 08 2015
10-K for Delcath Systems, Inc. May 06 2015
Delcath Reports 2015 First Quarter Financial Results May 06 2015
DELCATH SYSTEMS, INC. Files SEC form 10-Q, Quarterly Report May 06 2015
Delcath Reports 2015 First Quarter Financial Results May 06 2015
Most active Nasdaq-traded stocks Apr 29 2015
Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic... Apr 21 2015
Delcath Receives Approval To Expand Global Phase 2 HCC Program To Include Patients With Intrahepatic... Apr 21 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Apr 14 2015
Delcath to present at Needham & Company's 14th Annual Healthcare Conference Apr 10 2015
Delcath to present at Needham & Company's 14th Annual Healthcare Conference Apr 10 2015
Delcath Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program Apr 07 2015
Delcath Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program Apr 07 2015
Delcath Activates Prospective Registry In Europe Apr 02 2015
Delcath Activates Prospective Registry In Europe Apr 02 2015
DELCATH SYSTEMS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Mar 27 2015
Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual... Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK